Literature DB >> 24531339

Dynamics of myosin degradation in intensive care unit-acquired weakness during severe critical illness.

Tobias Wollersheim1, Janine Woehlecke, Martin Krebs, Jida Hamati, Doerte Lodka, Anja Luther-Schroeder, Claudia Langhans, Kurt Haas, Theresa Radtke, Christian Kleber, Claudia Spies, Siegfried Labeit, Markus Schuelke, Simone Spuler, Joachim Spranger, Steffen Weber-Carstens, Jens Fielitz.   

Abstract

IMPORTANCE: Intensive care unit (ICU)-acquired muscle wasting is a devastating complication leading to persistent weakness and functional disability. The mechanisms of this myopathy are unclear, but a disturbed balance of myosin heavy chain (MyHC) is implicated.
OBJECTIVE: To investigate pathways of myosin turnover in severe critically ill patients at high risk of ICU-acquired weakness.
DESIGN: Prospective, mechanistic, observational study.
SETTING: Interdisciplinary ICUs of a university hospital. PARTICIPANTS: Twenty-nine patients with Sequential Organ Failure Assessment (SOFA) scores of at least 8 on three consecutive days within the first 5 days in ICU underwent two consecutive open skeletal muscle biopsies from the vastus lateralis at median days 5 and 15. Control biopsy specimens were from healthy subjects undergoing hip-replacement surgery.
INTERVENTIONS: None. MAIN OUTCOME(S) AND MEASURE(S): Time-dependent changes in myofiber architecture, MyHC synthesis, and degradation were determined and correlated with clinical data.
RESULTS: ICU-acquired muscle wasting was characterized by early, disrupted myofiber ultrastructure followed by atrophy of slow- and fast-twitch myofibers at later time points. A rapid decrease in MyHC mRNA and protein expression occurred by day 5 and persisted at day 15 (P < 0.05). Expression of the atrophy genes MuRF-1 and Atrogin1 was increased at day 5 (P < 0.05). Early MuRF-1 protein content was closely associated with late myofiber atrophy and the severity of weakness. CONCLUSIONS AND RELEVANCE: Decreased synthesis and increased degradation of MyHCs contribute to ICU-acquired muscle wasting. The rates and time frames suggest that pathogenesis of muscle failure is initiated very early during critical illness. The persisting reduction of MyHC suggests that sustained treatment is required.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24531339     DOI: 10.1007/s00134-014-3224-9

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  41 in total

1.  Activation of caspase-3 is an initial step triggering accelerated muscle proteolysis in catabolic conditions.

Authors:  Jie Du; Xiaonan Wang; Christiane Miereles; James L Bailey; Richard Debigare; Bin Zheng; S Russ Price; William E Mitch
Journal:  J Clin Invest       Date:  2004-01       Impact factor: 14.808

2.  What is new in prevention of muscle weakness in critically ill patients?

Authors:  Matthias Eikermann; Nicola Latronico
Journal:  Intensive Care Med       Date:  2013-10-24       Impact factor: 17.440

3.  Acquired weakness, handgrip strength, and mortality in critically ill patients.

Authors:  Naeem A Ali; James M O'Brien; Stephen P Hoffmann; Gary Phillips; Allan Garland; James C W Finley; Khalid Almoosa; Rana Hejal; Karen M Wolf; Stanley Lemeshow; Alfred F Connors; Clay B Marsh
Journal:  Am J Respir Crit Care Med       Date:  2008-05-29       Impact factor: 21.405

Review 4.  Medical and economic implications of physical disability of survivorship.

Authors:  John P Kress; Margaret S Herridge
Journal:  Semin Respir Crit Care Med       Date:  2012-08-08       Impact factor: 3.119

5.  Identification of ubiquitin ligases required for skeletal muscle atrophy.

Authors:  S C Bodine; E Latres; S Baumhueter; V K Lai; L Nunez; B A Clarke; W T Poueymirou; F J Panaro; E Na; K Dharmarajan; Z Q Pan; D M Valenzuela; T M DeChiara; T N Stitt; G D Yancopoulos; D J Glass
Journal:  Science       Date:  2001-10-25       Impact factor: 47.728

Review 6.  Narrative review: ventilator-induced respiratory muscle weakness.

Authors:  Martin J Tobin; Franco Laghi; Amal Jubran
Journal:  Ann Intern Med       Date:  2010-08-17       Impact factor: 25.391

7.  Risk factors in critical illness myopathy during the early course of critical illness: a prospective observational study.

Authors:  Steffen Weber-Carstens; Maria Deja; Susanne Koch; Joachim Spranger; Florian Bubser; Klaus D Wernecke; Claudia D Spies; Simone Spuler; Didier Keh
Journal:  Crit Care       Date:  2010-06-18       Impact factor: 9.097

8.  Rapid disuse atrophy of diaphragm fibers in mechanically ventilated humans.

Authors:  Sanford Levine; Taitan Nguyen; Nyali Taylor; Michael E Friscia; Murat T Budak; Pamela Rothenberg; Jianliang Zhu; Rajeev Sachdeva; Seema Sonnad; Larry R Kaiser; Neal A Rubinstein; Scott K Powers; Joseph B Shrager
Journal:  N Engl J Med       Date:  2008-03-27       Impact factor: 91.245

9.  Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression.

Authors:  Stewart H Lecker; R Thomas Jagoe; Alexander Gilbert; Marcelo Gomes; Vickie Baracos; James Bailey; S Russ Price; William E Mitch; Alfred L Goldberg
Journal:  FASEB J       Date:  2004-01       Impact factor: 5.191

Review 10.  Clinical review: ventilator-induced diaphragmatic dysfunction--human studies confirm animal model findings!

Authors:  Samir Jaber; Boris Jung; Stefan Matecki; Basil J Petrof
Journal:  Crit Care       Date:  2011-03-11       Impact factor: 9.097

View more
  50 in total

1.  Focus on clinical neuroscience.

Authors:  Martin Smith; Giuseppe Citerio
Journal:  Intensive Care Med       Date:  2016-01-28       Impact factor: 17.440

2.  [Acute muscle loss in critically ill patients].

Authors:  S Weber-Carstens
Journal:  Med Klin Intensivmed Notfmed       Date:  2014-04-26       Impact factor: 0.840

Review 3.  The ICM research agenda on intensive care unit-acquired weakness.

Authors:  Nicola Latronico; Margaret Herridge; Ramona O Hopkins; Derek Angus; Nicholas Hart; Greet Hermans; Theodore Iwashyna; Yaseen Arabi; Giuseppe Citerio; E. Wesley Ely; Jesse Hall; Sangeeta Mehta; Kathleen Puntillo; Johannes Van den Hoeven; Hannah Wunsch; Deborah Cook; Claudia Dos Santos; Gordon Rubenfeld; Jean-Louis Vincent; Greet Van den Berghe; Elie Azoulay; Dale M Needham
Journal:  Intensive Care Med       Date:  2017-03-13       Impact factor: 17.440

4.  Physical activity, muscle strength, and exercise capacity 3 months after severe sepsis and septic shock.

Authors:  Rodrigo Cerqueira Borges; Celso R F Carvalho; Alexandra Siqueira Colombo; Mariucha Pereira da Silva Borges; Francisco Garcia Soriano
Journal:  Intensive Care Med       Date:  2015-06-25       Impact factor: 17.440

Review 5.  Steroids for acute respiratory distress syndrome?

Authors:  Catherine L Hough
Journal:  Clin Chest Med       Date:  2014-09-24       Impact factor: 2.878

6.  Risk factors for physical impairment after acute lung injury in a national, multicenter study.

Authors:  Dale M Needham; Amy W Wozniak; Catherine L Hough; Peter E Morris; Victor D Dinglas; James C Jackson; Pedro A Mendez-Tellez; Carl Shanholtz; E Wesley Ely; Elizabeth Colantuoni; Ramona O Hopkins
Journal:  Am J Respir Crit Care Med       Date:  2014-05-15       Impact factor: 21.405

7.  Diaphragm muscle fiber weakness and ubiquitin-proteasome activation in critically ill patients.

Authors:  Pleuni E Hooijman; Albertus Beishuizen; Christian C Witt; Monique C de Waard; Armand R J Girbes; Angelique M E Spoelstra-de Man; Hans W M Niessen; Emmy Manders; Hieronymus W H van Hees; Charissa E van den Brom; Vera Silderhuis; Michael W Lawlor; Siegfried Labeit; Ger J M Stienen; Koen J Hartemink; Marinus A Paul; Leo M A Heunks; Coen A C Ottenheijm
Journal:  Am J Respir Crit Care Med       Date:  2015-05-15       Impact factor: 21.405

8.  Diaphragmatic dysfunction in patients with ICU-acquired weakness and its impact on extubation failure.

Authors:  Boris Jung; Pierre Henri Moury; Martin Mahul; Audrey de Jong; Fabrice Galia; Albert Prades; Pierre Albaladejo; Gerald Chanques; Nicolas Molinari; Samir Jaber
Journal:  Intensive Care Med       Date:  2015-11-16       Impact factor: 17.440

9.  GTS-21 attenuates loss of body mass, muscle mass, and function in rats having systemic inflammation with and without disuse atrophy.

Authors:  Stefan J Schaller; Michio Nagashima; Martin Schönfelder; Tomoki Sasakawa; Fabian Schulz; Mohammed A S Khan; William R Kem; Gerhard Schneider; Jürgen Schlegel; Heidrun Lewald; Manfred Blobner; J A Jeevendra Martyn
Journal:  Pflugers Arch       Date:  2018-07-13       Impact factor: 3.657

Review 10.  Sarcopenia in critically ill patients.

Authors:  Muhammet C Kizilarslanoglu; Mehmet E Kuyumcu; Yusuf Yesil; Meltem Halil
Journal:  J Anesth       Date:  2016-07-04       Impact factor: 2.078

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.